The use of chitosan nanoparticles as carriers for expression plasmids represents a
major improvement in gene expression technology. We demonstrated previously that treatment
with chitosan interferon-γ (IFN-γ) plasmid deoxyribonucleic acid (DNA) nanoparticles
(chitosan interferon-γ nanogene [CIN]) led to in situ production of IFN-γ and a reduction
in inflammation and airway reactivity in mice, but the mechanism underlying the immunomodulatory
effects of CIN remains unclear. In this report, the effect of CIN treatment on the
immune responses of CD8+ T cells and dendritic cells was examined in a BALB/c mouse model of ovalbumin (OVA)-induced
allergic asthma. OT1 mice (OVA-T cell receptor [TCR] transgenic) were also used to
test the effects of CIN on OVA-specific CD8+ T cells. CIN treatment caused a reduction in IFN-γ production in a subpopulation of
OVA-specific CD8+ T cells cultured in vitro in the presence of OVA. CIN also reduced apoptosis of the
CD8+ T cells. Examination of dendritic cells from lung and lymph nodes indicated that CIN
treatment decreased their antigen-presenting activity, as evident from the reduction
in CD80 and CD86 expression. Furthermore, CIN treatment significantly decreased the
number of CD11c+b+ dendritic cells in lymph nodes, suggesting that endogenous IFN-γ expression may immunomodulate
dendritic cell migration and activation. CIN therapy results in a reduction in proinflammatory
CD8+ T cells and decreases the number and antigen-presenting activity of dendritic cells.

Keywords:

allergy; asthma; interferon

Review

The past decade has seen tremendous progress in gene expression technology. Several
investigators, including us, have used viral vectors for transient gene expression
with some success. The replication-deficient episomal adenovirus has been the workhorse
for gene therapy, but its toxicity and immunogenicity limit its clinical use [1-5]. Consequently, we have developed and tested a nonviral platform for gene expression
using plasmid deoxyribonucleic acids (pDNAs) that offers ease of preparation and use,
in vivo stability, heat resistance, and the capacity for large DNA sequences. The
plasmids do not integrate into mammalian genomes or replicate, yet they can persist
in host cells and express the cloned gene for several months. The drawback of pDNA
is its relatively low transfection efficiency under physiological conditions, especially
in non-dividing or slowly dividing cells, such as epithelial cells. Some improvement
in the transfection efficiency of pDNA has been made using liposomes or receptor targeting,
[6,7] but the approaches remain largely empirical.

One important development in gene transfer was the discovery that chitosan (a biocompatible
cationic polysaccharide derived from crustacean shell chitin) in the form of nanoparticles
(100-200 nm) could be used to deliver plasmids [8-12]. Chitosan has beneficial immunostimulatory, [13] anticoagulant, [14] wound-healing, [15] and antimicrobial properties [16]. It is nontoxic in humans, non-hemolytic, weakly immunogenic, and slowly biodegradable
and has been widely used in controlled drug delivery [9,17-21]. It also has mucoadhesive properties that increase transcellular and paracellular
transport across the mucosal epithelium, [22] which should facilitate gene delivery to mucosa- and bronchus-associated lymphoid
tissue. Chitosan, therefore, appears to possess all of the attributes of an ideal
gene delivery agent for effective nonviral gene expression therapy.

Since its discovery, interferon-γ (IFN-γ) has been extensively studied for its immunomodulatory
and antiviral activity. Mice lacking the IFN-γ receptor exhibit a T-helper (Th)2-like
cytokine profile, implying that IFN-γ may be a key cytokine in asthma [23]. IFN-γ provides the stimulatory signal for interleukin (IL)-12, [23,24] which is a strong inducer of the Th1 response. IL-12 inhibits Th2 cells by down-regulating
the production of IL-4 and IL-5. The IFN-γ-inducing factor IL-18 also shifts the immune
response froma Th2 to a Th1 state [25,26]. Local administration of aerosolized IFN-γ prevented antigen-induced eosinophil recruitment
in guinea pig trachea [27]. IFN-α, IFN-β, and -γ all inhibit leukotriene C4 production in murine macrophages, [28] but IFN-γ treatment of guinea pigs induced the release of prostanoids and nitric
oxide, which modify airway smooth muscle responses through effects on airway epithelium
[29].

Patients with allergic asthma exhibit lower than normal production of IFN-γ and IFN-γ-dependent
IL-12 in whole blood cultures after stimulation with a mitogen [30]. Because of the reciprocal regulation of T helper cells, it was anticipated that
increasing IFN-γ levels via chitosan pIFN-γ nanoparticles (chitosan interferon-γ nanogene
[CIN]) would promote a Th1 response by blocking Th2 cytokine production. IFN-γ upregulates
the IL-13Rα2 decoy receptor, leading to diminished IL-13 signaling [31] and reduced goblet cell hyperplasia and eosinophilia [32]. IFN-γ significantly inhibits release of leukotrienes from peripheral blood leukocytes
(PBLs) of allergic individuals after wasp venom immunotherapy [33] and decreases the production of sulfidoleukotrienes by human PBLs [34]. IFN-γ also downregulates transforming growth factor β and procollagen I and III
and decreases fibrosis in a mouse model of bleomycin-induced lung injury [35].

Exogenously supplied cytokines, such as IFN-γ, IL-12, and IL-18, have a short half-life
in vivo, and systemic administration at moderate to high doses can cause substantial
adverse effects [36,37]. To overcome these limitations to their therapeutic use, several investigators have
used expression vectors containing the cloned cytokine complementary deoxyribonucleic
acid (cDNA) under the regulation of a constitutive promoter as a means of boosting
in vivo production of specific cytokines. IFN-γ and IL-12 have proven effective as
prophylactics and adjuncts in therapy against diverse human diseases [38,39]. IL-12 gene transfer and expression in the mouse airway abrogated airway eosinophilia
and immunoglobulin E (IgE) synthesis, [40] and benefits from IFN-γ, IL-12, and IL-18 gene therapy have been documented in other
animal models [41-43]. However, the methods used to transduce plasmids in mice are not directly applicable
to humans because of the use of lipofectamine, which is toxic to humans.

Oromucosal therapy with recombinant IFN reduced the severity of viral infection, [44] but intranasal administration of IFN-γ pDNA has not been tested. Previous studies
from our laboratory demonstrated that intranasal administration of IFN-γ and IL-12
plasmids inhibited the induction of IL-5 messenger ribonucleic acid (mRNA), afforded
protection against viral infections, and significantly decreased airway inflammation
and airway hyperresponsiveness. In this article, we investigated the mechanism of
CIN-mediated immunomodulation using the mouse OVA-allergic asthma model. IFN-γ treatment
reduced cytokine production by a population of OVA-specific proinflammatory CD8+ T lymphocytes in the lung and led to decreased activation of dendritic cells.

Materials and methods

Animals

All mice were purchased from Jackson Laboratory (Bar Harbor, ME). BALB/c mice have
a predominantly Th2-type response to allergens, and these were used for most of the
experiments. The transgenic C57BL/6-TG(TcraTcrb)1100 mjb/j mice have CD8+ T cells specific for ovalbumin (OVA) amino acids 257 to 264, and these animals were
used in experiments to examine CIN effects on CD8+ cells. Female 6- to 8-week-old mice were maintained in pathogen-free conditions at
the University of South Florida College of Medicine vivarium. All procedures were
reviewed and approved by the Committee on Animal Research at the University of South
Florida College of Medicine and VA Hospital. A minimum of four mice were used in each
test group, and experiments were repeated twice.

Mouse IFN-γ cDNA was cloned in the mammalian expression vector pVAX (Invitrogen, San
Diego, CA), and complexed with chitosan, as described previously [45]. Briefly, plasmids in 25 mM Na2SO4 and chitosan (Vanson, Redmond, WA) dissolved in 25 mM Na acetate, pH 5.4, to a final
concentration of 0.02% were separately heated for 10 minutes at 55°C. After heating,
the chitosan and DNA were mixed, vortexed vigorously for 20 to 30 seconds, and stored
at room temperature until use. This treatment results in nanoparticles of 200 to 300
nm diameter as measured in transmission electron micrographs and by dynamic light
scattering. The effectiveness of intranasal chitosan nanoparticle-mediated gene transfer
in mice was tested with a vector that expresses green fluorescent protein (plasmid-encoding
green fluorescent protein [pEGFP]). Chitosan nanoparticles complexed with pEGFP were
prepared as above, and an amount containing 10 μg of pEGFP was administered intranasally
to mice. After 1, 3, and 7 days, the mice were euthanized and the lungs were removed
and fixed in buffered formalin. Whole lungs were embedded in paraffin, sectioned,
and examined for GFP by fluorescent microscopy, and an approximate percentage of GFP-positive
cells was estimated.

OVA Sensitization, CIN Treatment, and Preparation of Lung Sections

Mice were allergen-sensitized by intraperitoneal injection of 50 μg of OVA adsorbed
to 2 mg of alum (Imject, Pierce, Rockford, IL) followed by an intranasal challenge
with 50 μg of OVA after 1 or 2 weeks. To test the effects of boosting IFN-γ production
on allergen sensitization, mice were given an intranasal treatment of 10 μg of CIN,
chitosan with vector, or chitosan alone prior to intraperitoneal injection of OVA-alum.
This constitutes the prophylactic CIN regimen. Other groups of mice were given CIN
treatments after OVA sensitization as a therapeutic regimen. In both prophylactic
and therapeutic treatments, the mice were given a final challenge with OVA and then
euthanized, and the lungs from mice from each group were perfused in situ with phosphate-buffered
saline (PBS), removed, and fixed in 4% buffered formalin. Lungs from some mice in
each group were left unfixed and homogenized for lymphocyte isolation (see below).
Whole formalin-fixed lungs were paraffin-embedded, and 15-micron sections were made.
Two sections from each mouse were dewaxed, rehydrated, and labelled with either anti-IL-12Rb2-fluorescein
isothiocyanate (FITC) (Th1) or anti-T1/ST2L-rhodamine (Th2). Viewers examining the
stained sections were blinded as to the mouse group from which the slides were taken.
The stained sections were examined with a Nikon TE300 fluorescence microscope, and
representative areas were photographed.

C57BL/6 mice transgenic for the OVA-specific T cell receptor (TCR) (amino acids 257-264)
and C57BL/6 wildtype controls were given intranasal CIN treatment (10 μg), followed
by intraperitoneal sensitization with OVA-alum on day 1. On day 10, the mice were
again treated with CIN and then challenged intranasally with OVA. Twenty-four hours
after the challenge, the mice were euthanized and the lungs were perfused with PBS
and removed. Lungs were weighed, minced, and homogenized with Teflon homogenizers.
The homogenates were digested with collagenase (50 U/mL) in the presence of DNase
I (200 μg/mL) and passed through a 40-micron cell strainer to prepare single-cell
suspensions. This is a standard method of cell preparation and does not result in
selective loss or enrichment of lymphocytes or dendritic cells. Viabilities by trypan
blue dye exclusion were >80%. The cells were cultured for 20 hours with 50 μg/mL OVA.
Cultures were treated with 5 μg/mL brefeldin A for 4 hours prior to harvesting to
block secretion of intracellular cytokines. Class I restricted CD8+ T cells were surface-stained with OVA tetramer consisting of the OVA peptide Ser-Ileu-Ileu-Asn-Phe-Glu-Lys-Leu,
bound to four major histocompatibility complex (MHC)-I molecules conjugated with a
fluorescent phycoerythrin tag (Beckman/Coulter Immunomics, Fullerton, CA) and intracellularly
stained with FITC-conjugated anti-IFN-γ. Cells were counted by flow cytometry (FACScan,
BD Biosciences, San Jose, CA) with side-scatter/forward-scatter set for lymphocytes
and gating for CD8+ tetramer. Unstained cells were run as a control, and non-viable cells were distinguished
by staining with 7-amino-actinomycin D. Tetramers use a mutated form of MHC-I with
low binding affinity to CD8 on non-OVA-recognizing T cells, so there is no need to
run a tetramer control.

Apoptosis of OVA-Specific CD8+ T Lymphocytes from Lung

OVA-sensitized OT-1 mice were given therapeutic CIN treatment and 24 hours later were
challenged intranasally with OVA. Mice were euthanized 18 hours after OVA challenge.
Lungs were removed, homogenized, digested with collagenase and DNase, and passed through
a cell strainer to produce single-cell suspensions. The cells were pelleted by centrifugation
at 500 g for 5 minutes at 4°C, and then red blood cells were lysed by resuspending the cell
pellets twice in ice-cold lysis buffer (0.156 M NH4Cl, 10 mM KHCO3, 0.1 mM ethylenediaminetetraacetic acid, pH 7.3). Cells were resuspended in Roswell
Park Medium I (RPMI) 1640, plated, and incubated at 37°C for 18 hours. Non-adherent
cells consisting primarily of lymphocytes were removed by pipetting off the medium.
T lymphocytes were isolated by mouse T-cell enrichment columns (R & D Systems, Minneapolis,
MN) and analyzed for apoptosis using the TUNEL (terminal deoxynucleotidyl nick endlabeling)
assay (Promega, Madison, WI). The OVA-specific CD8+ T-cell population was labelled with phycoerythrin-tagged tetramer for OVA peptide
conjugated with MHC-I (Beckman/Coulter Immunomics). Unstained cells were used as a
control. The number of apoptotic OVA-specific CD8+ T cells was determined by flow cytometry (FACScan, BD Biosciences) and expressed as
a percentage of the total number of OVA-specific CD8+ cells.

Analysis of the Dendritic Cell Population in Lung Parenchyma

OVA-allergic BALB/c mice were treated therapeutically with CIN and then challenged
with OVA and euthanized 18 hours later. Lungs were removed, and single-cell suspensions
were prepared and plated as described above. In this case, however, mononuclear cells
were isolated from the cells that had adhered to the dishes after removal of the lymphocytes.
These were further purified using magnetic beads coated with anti-CD11c (Miltenyi
Biotec, Auburn, CA) with cell recoveries in the range of 3 to 5 million per gram of
lung tissue. The CD11c+ cells were then seeded into 12-well plates at 5 × 105 cells per well and cultured for 48 hours in the presence of 10 μg of chitosan-pVAX
(vector control) or CIN. Cells were scraped from the wells, resuspended in PBS + 3%
fetal calf serum (FCS), stained with phycoerythrin meaning (PE)-antiCD11c and individually
with FITC-anti-I-Ad, -CD40, and -CD80. CD11c+ cells expressing each of the dendritic cell activation markers were counted by flow
cytometry (FACScan, BD Biosciences) with appropriate controls.

In another set of experiments, lung mononuclear cells were isolated as described above
but were not cultured. The cells were stained with FITC-anti-CD11c and rhodamine-anti-CD11b
and counted by flow cytometry (FACScan, BD Biosciences). The numbers of CD11c+b+ cells were expressed as a percentage of the total CD11c+ cells.

Analysis of the Dendritic Cell Population in BAL Fluid

BALB/c mice were sensitized with OVA, challenged by intranasal administration of OVA,
and 2 months later given CIN treatment. They were again challenged with OVA and euthanized
18 hours later. Lungs were lavaged with 1 mL of PBS in two 0.5 mL aliquots introduced
and withdrawn through the trachea. The BAL fluid was centrifuged 10 minutes at 300
g, and cells were resuspended in PBS. Buffered paraformaldehyde was added to a final
concentration of 4%, and cells were fixed for 10 minutes at room temperature. Cells
were washed with PBS and resuspended in PBS with 3% FCS. Aliquots of the cell suspension
were all stained for CD11c and CD11b and individually for CD40, CD80, CD86, and I-Ad.
Appropriate isotype controls and positive fluorescence markers for each fluor were
also prepared. Cells expressing each of the four dendritic cell activation markers
were counted by three-colour flow cytometry (FACSCalibur, BD Biosciences) gated on
CD11c+ and CD11b+ cells.

Analysis of the Dendritic Cell Population in Lymph Nodes

BALB/c mice were treated as described above for BAL fluid isolation, and peribronchial
lymph nodes were removed at euthanasia. Single-cell suspensions were prepared by maceration
of the lymph nodes through 40-micron cell strainers, and CD11c+ cells were isolated by magnetic bead separation. The cells were stained for CD11b
and separately for each of the dendritic cell activation markers CD40, CD80, CD86,
and I-Ad and were counted by flow cytometry (FACScan, BD Biosciences).

IFN-Inducible Target Gene Array Analysis in Dendritic Cells

To identify which genes were up- or downregulated by CIN treatment, CD11c+ dendritic cells were isolated from lung cell suspensions of OVA-allergic/-challenged
BALB/c mice (two mice per isolation) using anti-CD11c conjugated to magnetic beads
(Miltenyi Biotech, Auburn, CA). Total ribonucleic acid (RNA) was purified from dendritic
cells of mice treated with control vector or CIN, converted to cDNA using reverse
transcriptase, and labelled with biotinylated deoxyuridine triphosphate (dUTP). The
labelled cDNA was hybridized to a TranSignal Interferon-inducible Gene Array membrane
(Panomics, Fremont, CA), and signals were detected by chemiluminescence on x-ray film.
The resulting film image was scanned, and densitometry calculations were done using
the ScionImage (Scion Corporation, http://www.scioncorp.comwebcite) program to compare the results from untreated mice with those from CIN-treated mice.
The gene array analysis was repeated once with a similar expression profile.

BALB/c mice were OVA-sensitized and challenged and given CIN treatment or chitosan-control
vector only. After treatment, peribronchial lymph nodes were removed and macerated
through 40-micron cell strainers. Single-cell suspensions were then mixed with anti-CD11c
magnetic beads (Miltenyi Biotec, Auburn, CA), and bound cells were collected according
to the manufacturer's protocol. Total RNA was prepared from the CD11c+ cells, and 32P-UTP (Amersham, Piscataway, NJ)-labelled probes were generated by in vitro transcription
of cytokine-specific multiprobe template sets (BD Pharmingen, San Diego, CA) using
T7 RNA polymerase. The labelled probes were purified, adjusted to 3 × 105 cpm/mL, and hybridized to 5 μg of each RNA. The reactions were subsequently digested
with ribonuclease (Rnase) followed by proteinase K and extracted with phenol-chloroform.
After ethanol precipitation with 4 M ammonium acetate, the protected samples were
resuspended in loading buffer and separated on a 6% Tris-borate-EDTA (TBE)-urea gel
(Novex Invitrogen, Carlsbad, CA). The gel was placed on filter paper, dried under
a vacuum, and exposed to Kodak X-OMAT-AR film with intensifying screen at -80°C.

A reverse transcriptase-polymerase chain reaction (RT-PCR) was carried out on total
RNA from CD11c+ cells isolated by magnetic bead separation from peribronchial lymph nodes of OVA-sensitized/OVA-challenged
BALB/c mice treated with vector or CIN. PCR primers specific for the indicated Toll-like
receptors (TLRs) were used along with β-actin as control, and amplification was performed
for 25, 30, and 35 cycles.

Statistical Analysis

Each test group of mice contained at least four animals, and experiments were repeated
twice. Values for all measurements are expressed as means ± SEMs. Groups were compared
by analysis of variance and through the use of paired Student t-tests. Differences between groups were considered significant at p < .05.

Results and Discussion

Expression in the Lung of a Chitosan Nanoparticle-Delivered Plasmid

To determine that pDNAs can be transported in chitosan nanoparticles and expressed
in the lung epithelium, pEGFP was complexed with chitosan nanoparticles and administered
intranasally to BALB/c mice. At 1, 3, and 7 days thereafter, mice were euthanized,
lungs were removed, and sections were examined by fluorescence microscopy for GFP
expression. By 3 days after pEGFP nanoparticle administration, roughly half of the
lung epithelial cells appeared to be positive for EGFP (data not shown), and expression
of GFP continued for at least 7 days. We conclude that intranasal delivery of plasmids
by means of chitosan nanoparticles results in a sustained expression of the encoded
protein in the lung and provides an effective means of supplying therapeutic or prophylactic
levels of an immunomodulatory molecule.

Effects of CIN Therapy on T Lymphocytes

In a previous study, we found that CIN treatment significantly lowered airway hyperresponsiveness
to methacholine and reduced lung histopathology in a BALB/c mouse model of OVA-allergic
asthma [46]. CIN-treated mice produced higher levels of IFN-γ but less of the Th2 cytokines IL-4
and IL-5 and had reduced OVA-specific serum IgE compared with mice given vector alone.
Lung infiltration by eosinophils was significantly reduced by CIN therapy, and overproduction
of mucus was inhibited within 6 hours of CIN delivery by induced apoptosis of goblet
cells. In this study, we sought to understand the mechanism of CIN action.

T cells play a critical role in the pathology of asthma and therefore may be potential
targets of agents such as CIN for ameliorating asthmatic symptoms. CD4+ T helper cells can either promote (Th2) or inhibit (Th1) the inflammation of asthma
depending on their phenotype and the presence or absence of specific cytokines. To
examine the effects of CIN treatment on CD4+ T lymphocyte populations in the lung, sections from control and CIN-treated mice were
stained with rhodamine-labelled anti-T1/ST2L, specific for Th2 cells, or with FITC-labelled
anti-IL-12Rβ2 for Th1 cells. Sections were examined in a blinded fashion by fluorescence
microscopy, and representative photographs were made to show comparisons of controls
with CIN-treated animals. Lungs from CIN-treated mice showed qualitatively fewer Th2
cells and either the same or slightly more Th1 cells than control mice (Figure 1A).

Figure 1.Chitosan interferon-γ nanogene (CIN) modulates T-cell responses in ovalbumin (OVA)-allergic
mice. A, Localization of T helper cells in the lungs of C57BL/6 mice using antibody to interleukin-12Rβ
(Th1) and T1/ST2L (Th2). B, Changes in interferon-γ (IFN-γ) production by OVA-specific CD8+ T cells from the lung. T-cell receptor OVA-specific OT1 mice were treated with CIN
and then sensitized with OVA and challenged 10 days later. T lymphocytes were isolated
from lungs, cultured with OVA, and stained with tetramer to label OVA-specific CD8+ T cells. IFN-γ was identified by intracellular cytokine staining and counted by flow
cytometry after gating for tetramer-labelled cells. C, Apoptosis of OVA-specific CD8+ T cells from lungs determined by TUNEL assay and measured by flow cytometry. The data
are based on cytometry of a minimum of 15,000 cells and were substantiated by a repeat
experiment.

Both CD4+ and CD8+ T lymphocytes are involved in the immune response to allergens. To determine if CIN
therapy affects the activity of antigen-specific CD8+ T cells, C57BL/6-OT1 mice carrying the transgene for the T-cell receptor specific
for the OVA epitope, amino acids 257 to 264, were given intranasal CIN and then sensitized
by intraperitoneal injection with OVA (day 1). They were again treated with CIN and
then challenged with OVA intranasally on day 10. Lung lymphocytes were isolated 24
hours later and cultured in the presence of OVA and brefeldin A for 20 hours. Cell
viability was >80% (trypan blue dye exclusion test). The OVA-specific CD8+ T cells were stained using a tetramer for the 257- to 264-amino acid OVA peptide,
and the IFN-γ produced during OVA exposure was labelled by intracellular cytokine
staining. After appropriate gating, the cells were counted by flow cytometry. The
results (Figure 1B) show that CIN treatment caused a decrease in the number of IFN-γ-producing, OVA-specific
CD8+ T cells in the lungs of OVA-challenged mice.

To further assess the fate of OVA-specific CD8+ T cells, OVA-allergic C57 mice were treated with CIN and 24 hours later challenged
intranasally with OVA. Mice were euthanized 18 hours after challenge, and the lungs
were used to prepare single-cell suspensions of T cells. The OVA-specific CD8+ T-cell population was labelled with phycoerythrin-tagged tetramer for OVA peptide
conjugated with MHC-I. CD8+ cells were analyzed for apoptosis using the TUNEL assay (Promega) and counted by FACScan
flow cytometry. The percentage of total OVA-specific CD8+ T cells that were apoptotic was lower in CIN-treated mice compared with untreated
controls (Figure 1C); therefore, the decrease in IFN-γ production observed in the CD8+ T cells does not appear to be the result of destruction of the cells but represents
an IFN-γ-mediated downregulation of IFN-γ production by a specific subpopulation of
lymphocytes.

These CIN-mediated alterations in T-cell populations support the hypothesis that CD8+ T cells are important in allergen-induced lung pathology and that at least a part
of the protective effect of CIN treatment can be attributed to a reduction in numbers
of a specific CD8+ T-cell population. Intranasal administration of antigen to rats was reported to induce
T-cell activation concurrent with a burst of IFN-γ production, whereas subsequent
antigen exposure produced apoptosis and tolerization in a T-cell population [47]. Also, IFN-γ has been reported to induce apoptosis of CD8+ T cells [48,49]. Our results in this OVA-allergic asthma model would suggest that IFN-γ may have
an autocrine effect, downregulating its own production in T lymphocytes.

Effects of CIN Therapy on Dendritic Cells

Antigen presentation is a key process in determining the magnitude of an immune response
to an allergen such as OVA. Since antigen-presenting cells commonly take up extracellular
particles, it is reasonable to suppose that CIN therapy, which uses chitosan nanoparticles,
might involve cells that interact with or take up the particles and directly influence
the immune response. Dendritic cells are the predominant antigen-presenting species
in regulating T-cell activation and thus may participate in the protective effect
of CIN therapy.

To determine whether CIN therapy affects the activity of lung dendritic cells, CD11c+ mononuclear cells were isolated from lungs of OVA-allergic mice with or without CIN
treatment and incubated with control nanoparticles alone or with CIN. Flow cytometry
was done on cell suspensions after labelling for CD11c and for each of the following
markers: I-Ad, CD40, and CD80. The results showed an increase in CD40 but a decrease
in expression of CD80 and I-Ad in dendritic cells from CIN-treated mice compared with
controls (Figure 2A). CD40 is a cell surface receptor related to the tumour necrosis factor receptor
superfamily that binds to CD40 ligand, which is expressed primarily by T cells. Upregulation
of CD40 may influence the interaction of lung dendritic cells with allergen-specific
T lymphocytes.

Figure 2.Effect of chitosan interferon-γ nanogene (CIN) therapy on expression of dendritic
cell activation markers. A, In vitro CIN treatment of CD11c+ cells from the lungs of ovalbumin (OVA)-allergic mice. BALB/c mice were OVA sensitized
and challenged with OVA and sacrificed 18 hours later. Lungs were removed and CD11c+ dendritic cells were isolated as described in Materials and Methods. Dendritic cells
were cultured with vector alone (control) or with CIN. Flow cytometry was performed
on cell suspensions after labelling for CD11c (fluorescein isothiocyanate [FITC])
and for each of the following markers: I-Ad, CD40, and CD80 phycoerythrin (PE). Counts
were done using a FACScan gated for CD11c cells. The figure shows the percentage of
cells that were positive for CD11c and for each of the markers. Activation marker
expression in CD11c+ cells from the bronchoalveolar lavage (BAL) fluid and lymph nodes of OVA-allergic
mice treated with CIN (B). Mice were treated as described in Materials and Methods, and CD11c+ cells were isolated from BAL fluid and lymph nodes. Cells were analyzed by flow cytometry
for the expression of CD40, CD80, CD86, and I-Ad gated to CD11c+b+. The data are based on cytometry of a minimum of 15,000 cells and were substantiated
by a repeat experiment.

To further examine the potential effects of CIN on dendritic cells, ex vivo cultures
from BAL fluid and from thoracic lymph nodes were prepared from mice with or without
CIN treatment and tested for expression of CD40, the costimulatory molecules CD80
and CD86, and I-Ad (MHC-II). The results showed that CIN treatment decreased expression
of CD80 and CD86 on dendritic cells from both BAL fluid and lymph nodes (Figure 2B). CD40 expression was decreased in lymph node dendritic cells, whereas the expression
of I-Ad was unaffected in both DC types. These results indicated that dendritic cells
from lung lavage or from peribronchial lymph nodes can be partially inactivated by
CIN treatment, and their capacity to activate T cells may consequently be reduced.

Survival of mature dendritic cells is necessary for subsequent interaction with T
lymphocytes, and CIN may affect apoptosis of dendritic cells and their activation.
To examine this possibility, OVA-allergic mice were challenged with OVA and then 2
months later given CIN and challenged again with OVA. Mononuclear cells were isolated
from lungs as described above, and the relative numbers of CD11c+ and CD11b+ cells were determined by flow cytometry. CIN treatment decreased the number of CD11c+b+ cells and increased the number of CD11c+b- cells (Figure 3). CD11c+b+ cells are considered to be the most active antigen-presenting cells, so the observation
that CIN therapy caused a significant reduction (fivefold) in the numbers of CD11c+b+ cells is consistent with the other data in supporting the idea that CIN treatment
decreases the inflammatory response to an allergen by inhibiting dendritic cell activation
of OVA-specific T cells.

Figure 3.Effect of chitosan interferon-γ nanogene (CIN) therapy on the dendritic cell population
in the lung. Ovalbumin-allergic/-challenged mice were treated with or without CIN therapy as
described in Materials and Methods, and mononuclear cells were isolated from the lungs.
Cells were stained with fluorescein isothiocyanate (FITC)-anti-CD11c and rhodamine
(Rhod)-anti-CD11b, and CD11c+b+ cells were counted by flow cytometry. Values given are the percentage of total CD11c+ cells that are also CD11b+. The data are based on cytometry of a minimum of 15,000 cells and were substantiated
by a repeat experiment.

Alteration of Dendritic Cell Gene Expression by CIN Treatment

Although CD40, CD80, and CD86 are key markers of activated dendritic cells, many other
genes are important in the allergic immune response and may be up- or downregulated
by CIN treatment. To determine how CIN affects gene expression, total RNA was isolated
from the lung dendritic cells of control and CIN-treated mice, converted to cDNA,
and labelled as probes, which were hybridized to a mouse TranSignal Interferon-inducible
Gene Array membrane. The x-ray film images of the control and CIN arrays were scanned,
and spot densities were analyzed and compared using the ScionImage program. A two- to threefold increase or decrease in spot density was considered significant,
and an example of some CIN-upregulated genes is shown in Figure 4A. The results demonstrate that such arrays can be useful in detecting significant
changes in gene expression and that novel changes can be identified in lung dendritic
cells from CIN-treated mice compared with controls. To confirm CIN-mediated changes
in expression of selected cytokine genes, the RNAs were analyzed further by RNase
protection assay. The results show that CIN treatment augments expression of IL-12
p40, IL-18, IL-1α, and IFN-γ in dendritic cells (Figure 4B). Dendritic cells are activated by signals generated through recognition of foreign
antigens by their surface TLRs. To examine the possibility that the observed changes
in gene expression were due to CIN-mediated differential expression of TLR genes,
the expression of a number of TLR genes on peribronchial lymph node dendritic cells
(purified by CD11c magnetic beads) was assayed by RT-PCR. The results indicated that
CIN treatment did not affect expression of TLR-2, -4, -5, -6, and -9 at the mRNA level
(Figure 5) and, therefore, that CIN affects the activation of dendritic cells independently
of TLR signalling.

Figure 5.Expression of Toll-like receptors (TLRs) on dendritic cells. Total ribonucleic acid (RNA) was purified from CD11c+ cells isolated by magnetic bead separation from peribronchial lymph nodes of mice
with or without chitosan interferon-γ nanogene treatment. RNAs were reverse-transcribed
and used as a template for reverse transcriptase-polymerase chain reaction (PCR) with
primer pairs and PCR conditions specific for the indicated TLRs. The results of PCRs
for 25 cycles are shown with β-actin used as a control (one typical experiment of
two).

Conclusion

These studies demonstrate that IFN-γ delivered via intranasal CIN treatment reduces
the allergic immune response by means of its effects on CD8+ T cells and dendritic cells in mice. The results are consistent with a mechanism whereby
CIN therapy decreases the innate immune response by altering cytokine production of
a CD8+ T-cell subpopulation and by decreasing the antigen-presenting activity of dendritic
cells.

Note

These studies were supported by grant 5RO1 HL 071101-02 and VA Merit Review and Career
Scientist Award to S.S.M and the Florida Biomedical Research Foundation Bankhead-Coley
Award and Mabel and Ellsworth Simmons Professorship to S.S.M., and by the Joy McCann
Culverhouse endowment to the University of South Florida Division of Allergy and Immunology.

Acknowledgements

We would like to thank Sylvia Montalvo for her assistance in preparation of the manuscript.